THE ADMINISTRATION OF BIOCOMPATIBLE IRON OXIDE NANOPARTICLES IN PARKINSON’S DISEASE

This study provides a synthesis of the most recent existing research in the literature and an analysis of ScienceDirect, and Google Scholar databases related to the administration of iron oxide nanoparticles in Parkinson’s disease. The total number of articles published in the last 10 years was determined using specific key terms. The pathogenesis of Parkinson’s disease is attributed to the
reduction of dopaminergic activity in neurons of the substantia nigra, leading to deficits in motor control, manifested as muscle rigidity, resting tremor, and coordination disturbances. The main challenge regarding drug administration is the blood-brain barrier, which prevents the passage of medications, resulting in less effective treatment. The advantage of administering iron oxide nanoparticles in Parkinson’s disease mainly lies in their small size, which facilitates their passage through the blood-brain barrier.